Maintenance Golimumab Treatment in Pediatric UC Patients With Moderately to Severely Active UC: PURSUIT PEDS PK Long-Term Study Results. Issue 4 (4th August 2020)

• Record Type: Journal Article
• Authors: Hyams, Jeffrey S; O'Brien, Christopher D; Padgett, Lakshmi; Rosh, Joel R; Turner, Dan; Veereman, Genevieve; Griffiths, Anne M; Heyman, Melvin B; Wahbeh, Ghassan; Adedokun, Omoniyi J; Strauss, Richard S; Lynch, John P; Chan, Daphne
• Is Part Of: Crohn's & colitis 360. Volume 2:Issue 4(2020)
• Publication Date: 2020-08-04
• Subjects: ulcerative colitis -- clinical response -- clinical remission; Crohn's disease -- Periodicals; Colitis -- Periodicals; 616.344
• DOI: 10.1093/crocol/otaa063
• Languages: English
• ISSNs: 2631-827X

Abstract

Abstract: Background: Long-term safety, pharmacokinetics, and efficacy of open-label golimumab therapy in children with moderate–severe ulcerative colitis were evaluated. Methods: Week-6 golimumab responders (Mayo score decrease of ≥30% and ≥3 points from baseline, rectal bleeding subscore of 0/1 or ≥1 decrease from baseline) entered the long-term extension at week 14 and received maintenance therapy (subcutaneous, q4w). Patients ≥45 kg could receive at-home treatments at week 18. Pharmacokinetic, safety, and efficacy results were summarized through week 126 (2 years). Results: Among 35 enrolled children, 21 (60%) responded at week 6 and 20 entered the long-term extension (median age of 14.5 years and median weight of 46.1 kg). Eleven of 20 patients (55%) completed 2 years of treatment. No anaphylactic or serum sickness-like reactions, opportunistic infections, malignancies, tuberculosis, or deaths occurred. The safety profile of golimumab from weeks 14 through 126 and that observed through week 14 was generally consistent. Median trough golimumab concentrations in evaluable patients were consistent from weeks 14 (1.39, interquartile range 0.67–3.60) through 102 (1.18, 0.78–2.16), but higher at week 110 (4.10, 1.30–4.81). The incidence of antigolimumab antibodies increased from 10% (2/20) at week 30 to 25.0% (5/20) at week 126; 1 patient had neutralizing antibodies. At week 110, 50% (10/20) of patients were in remission (ie, Pediatric Ulcerative Colitis Activity Index <10). Among all enrolled patients, 28.6% (10/35) achieved remission at week 110. Conclusions: Among children with ulcerative colitis who initially responded to golimumab induction and received q4w maintenance treatment in the long-term extension, 50% showed continued clinical benefit through 2 years. No new safety signals were observed. Lay Summary: Among enrolled children, 21/35 responded at week 6; 20 entered the long-term extension at week 14. Clinical remission rates and clinically meaningful changes remained stable from weeks 30 to 110. No serious anaphylactic or serum sickness-like reactions, opportunistic infections, malignancies, tuberculosis, or deaths occurred.